Publications by authors named "Jeffrey D Kearns"

Claim this Profile
Q
QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life.
Eshita Khera, Lekshmi Dharmarajan, Dominik Hainzl, Volker Engelhardt, Helena Vostiarova, Jeffrey D Kearns

J Pharmacokinet Pharmacodyn· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current practices for QSP model assessment: an IQ consortium survey.
Jason R Chan, Richard Allen, Britton Boras, Antonio Cabal, Valeriu Damian, Jeffrey D Kearns

J Pharmacokinet Pharmacodyn· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A model-informed method to retrieve intrinsic from apparent cooperativity and project cellular target occupancy for ternary complex-forming compounds.
Richard R Stein, Marianne Fouché, Jeffrey D Kearns, Hans-Joerg Roth

RSC Chem Biol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events.
Anette C Karle, Matthias B Wrobel, Stephan Koepke, Michael Gutknecht, Sascha Gottlieb, Jeffrey D Kearns

Sci Transl Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab.
Jeffrey D Kearns, Paul Wassmann, Ufuk Olgac, Marie Fichter, Brigitte Christen

Sci Transl Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Andreas Weiss, Edwige Lorthiois, Louise Barys, Kim S Beyer, Claudio Bomio-Confaglia, Jeffrey D Kearns

Cancer Discov· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating Between Right, Wrong, and Relevant: The Use of Mathematical Modeling in Preclinical Decision Making.
Anna Kondic, Dean Bottino, John Harrold, Jeffrey D Kearns, C J Musante

Front Pharmacol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma.
E Josue Ruiz, Adan Pinto-Fernandez, Andrew P Turnbull, Linxiang Lan, Thomas M Charlton, Jeffrey D Kearns

Elife· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling Approaches.
Anwesha Chaudhury, Xu Zhu, Lulu Chu, Ardeshir Goliaei, Carl H June, Jeffrey D Kearns

J Clin Pharmacol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.
Jessica B Casaletto, Melissa L Geddie, Adnan O Abu-Yousif, Kristina Masson, Aaron Fulgham, Jeffrey D Kearns

Proc Natl Acad Sci U S A· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.
James M Cleary, Autumn J McRee, Geoffrey I Shapiro, Sara M Tolaney, Bert H O'Neil, Jeffrey D Kearns

Invest New Drugs· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease.
Davide Corti, Jeffrey D Kearns

Curr Opin Immunol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
Sabrina Arena, Giulia Siravegna, Benedetta Mussolin, Jeffrey D Kearns, Beni B Wolf

Sci Transl Med· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
Jeffrey D Kearns, Raghida Bukhalid, Mark Sevecka, Gege Tan, Nastaran Gerami-Moayed

Mol Cancer Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IκBβ enhances the generation of the low-affinity NFκB/RelA homodimer.
Rachel Tsui, Jeffrey D Kearns, Candace Lynch, Don Vu, Kim A Ngo

Nat Commun· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual delayed feedback provides sensitivity and robustness to the NF-κB signaling module.
Diane M Longo, Jangir Selimkhanov, Jeffrey D Kearns, Jeff Hasty, Alexander Hoffmann

PLoS Comput Biol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies.
Brian D Harms, Jeffrey D Kearns, Sergio Iadevaia, Alexey A Lugovskoy

Methods· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Control of RelB during dendritic cell activation integrates canonical and noncanonical NF-κB pathways.
Vincent F-S Shih, Jeremy Davis-Turak, Monica Macal, Jenny Q Huang, Julia Ponomarenko, Jeffrey D Kearns

Nat Immunol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
Brian D Harms, Jeffrey D Kearns, Stephen V Su, Neeraj Kohli, Ulrik B Nielsen

Methods Enzymol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nuclear export of the NF-κB inhibitor IκBα is required for proper B cell and secondary lymphoid tissue formation.
Shelly M Wuerzberger-Davis, Yuhong Chen, David T Yang, Jeffrey D Kearns, Paul W Bates

Immunity· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetic control of negative feedback regulators of NF-kappaB/RelA determines their pathogen- and cytokine-receptor signaling specificity.
Vincent F-S Shih, Jeffrey D Kearns, Soumen Basak, Olga V Savinova, Gourisankar Ghosh

Proc Natl Acad Sci U S A· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating computational and biochemical studies to explore mechanisms in NF-{kappa}B signaling.
Jeffrey D Kearns, Alexander Hoffmann

J Biol Chem· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators IkappaBalpha and A20.
Shannon L Werner, Jeffrey D Kearns, Victoria Zadorozhnaya, Candace Lynch, Ellen O'Dea

Genes Dev· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UV as an amplifier rather than inducer of NF-kappaB activity.
Ellen L O'Dea, Jeffrey D Kearns, Alexander Hoffmann

Mol Cell· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stabilization of RelB requires multidomain interactions with p100/p52.
Amanda J Fusco, Olga V Savinova, Rashmi Talwar, Jeffrey D Kearns, Alexander Hoffmann

J Biol Chem· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis